Chulalongkorn University
This randomized, double-blind clinical trial evaluates the therapeutic effects of curcumin in nanogels compared to 0.1% fluocinolone acetonide oral paste in the management of atrophic-erosive oral lichen planus (OLP). The study aims to determine whether curcumin nanogels, a natural treatment with enhanced bioavailability, are as effective and better tolerated than standard corticosteroid therapy.
Atrophic-erosive Oral Lichen Planus
Curcumin in Nanogels
0.1% Fluocinolone Acetonide Oral Paste
NA
Oral lichen planus (OLP) is a chronic, immune-mediated inflammatory condition that causes painful mucosal lesions and significantly impairs patients' quality of life. Although topical corticosteroids are the standard treatment, their long-term use is associated with adverse effects. Curcumin, a natural compound with anti-inflammatory and antioxidant properties, has shown promise as an alternative treatment. However, its clinical application is limited by poor bioavailability. This randomized, double-blind, controlled clinical trial aims to compare the therapeutic effects of curcumin in nanogels and 0.1% fluocinolone acetonide oral paste in patients with atrophic-erosive OLP. Thirty eligible participants will be randomly assigned to either the curcumin nanogel or fluocinolone group, and treatment outcomes will be evaluated using the Oral Lichen Planus Disease Activity Scale (OLP-DAS) and a patient satisfaction questionnaire over a 4-week period. The study is conducted at the Faculty of Dentistry, Chulalongkorn University, and seeks to evaluate whether curcumin nanogels offer comparable therapeutic efficacy to corticosteroids, with potentially fewer side effects.
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 30 participants |
Masking : | DOUBLE |
Primary Purpose : | TREATMENT |
Official Title : | THE THERAPEUTIC EFFECT OF CURCUMIN IN NANOGELS COMPARED TO 0.1% FLUOCINOLONE ACETONIDE ORAL PASTE IN THE MANAGEMENT OF ATROPHIC-EROSIVE ORAL LICHEN PLANUS |
Actual Study Start Date : | 2025-06-01 |
Estimated Primary Completion Date : | 2026-06-30 |
Estimated Study Completion Date : | 2026-06-30 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
No Location Found